BCL2 and neoplasm: As expected, our gene expression results demonstrated that the triple-drug combination (TME) significantly reduced the levels of BCL2 and enhanced the expression levels of BAX, BAD, caspase-9, 8 and 3 when compared to that of tumor-control group (p < 0.0001).